David A. Siegel Atara Biotherapeutics, Inc. Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $990,011 - $1.98 Million	-117,300 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $4.81 Million - $6.51 Million	-327,100 Reduced 73.6%	117,300 $1.85 Million
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $2.47 Million - $3.68 Million	-205,800 Reduced 31.65%	444,400 $7.96 Million
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $2.02 Million - $2.6 Million	-156,800 Reduced 19.43%	650,200 $10.1 Million
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $1.54 Million - $2.28 Million	110,000 Added 15.78%	807,000 $11.6 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $3.87 Million - $8.01 Million	305,200 Added 77.9%	697,000 $13.7 Million
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $1.25 Million - $1.66 Million	104,500 Added 36.37%	391,800 $5.08 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $274,092 - $543,452	36,400 Added 14.51%	287,300 $4.19 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $284,500 - $889,000	50,000 Added 24.89%	250,900 $2.14 Million
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $1.47 Million - $2.27 Million	135,200 Added 205.78%	200,900 $3.31 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $790,371 - $1.31 Million	65,700 New	65,700 $928,000
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $343,490 - $426,300	-9,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $344,470 - $504,210	9,800 New	9,800 $360,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.